Literature DB >> 23073729

Dexmedetomidine versus remifentanil sedation during awake fiberoptic nasotracheal intubation: a double-blinded randomized controlled trial.

Rong Hu1, J X Liu, Hong Jiang.   

Abstract

BACKGROUND: Awake fiberoptic nasotracheal intubation is usually performed in patients with an anticipated difficult airway. This study compares dexmedetomidine and remifentanil for conscious sedation during fiberoptic intubation.
METHODS: Forty patients undergoing elective awake fiberoptic nasotracheal intubation were allocated randomly to receive either dexmedetomidine (n = 20) or remifentanil (n = 20). Primary outcome measures were endoscopy, intubation, and post-intubation conditions as scored by the attending anesthesiologist. Other parameters included the time taken to achieve the desired level of sedation, endoscopy time, intubation time, and hemodynamic changes during the procedure. An interview was conducted 24 h after surgery to evaluate patients' recall of and satisfaction with the procedure.
RESULTS: The median [interquartile range] endoscopy score (graded 0-5) in the dexmedetomidine group (2 [1-2]) was significantly better than in patients who received remifentanil (3 [2-3]; p < 0.01). Recall of intubation was significantly lower in the dexmedetomidine group (p = 0.027). Dexmedetomidine provided better patient satisfaction than remifentanil (2 [1-2] and 2 [2-3], respectively; p = 0.022). Patients in the dexmedetomidine group had fewer heart rate responses during endoscopy and intubation as compared to the remifentanil group (p < 0.001 and p = 0.004, respectively). Peripheral oxygen saturation was less in the remifentanil group during endoscopy (p = 0.003). There were no significant differences in intubation and post-intubation conditions.
CONCLUSIONS: Both dexmedetomidine and remifentanil were effective as sedatives in patients undergoing awake fiberoptic nasotracheal intubation. Compared with remifentanil, dexmedetomidine offered better endoscopy scores, lower recall of intubation, and greater patient satisfaction, with minor hemodynamic side effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073729     DOI: 10.1007/s00540-012-1499-y

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  26 in total

1.  Remifentanil as single agent to facilitate awake fibreoptic intubation in the absence of premedication.

Authors:  R Vennila; A Hall; M Ali; N Bhuiyan; D Pirotta; D A Raw
Journal:  Anaesthesia       Date:  2011-03-28       Impact factor: 6.955

2.  The effects of increasing plasma concentrations of dexmedetomidine in humans.

Authors:  T J Ebert; J E Hall; J A Barney; T D Uhrich; M D Colinco
Journal:  Anesthesiology       Date:  2000-08       Impact factor: 7.892

3.  Remifentanil sedation for awake fibreoptic intubation with limited application of local anaesthetic in patients for elective head and neck surgery.

Authors:  O H Mingo; K J Ashpole; C J Irving; M W M Rucklidge
Journal:  Anaesthesia       Date:  2008-07-31       Impact factor: 6.955

4.  Remifentanil target-controlled infusion vs propofol target-controlled infusion for conscious sedation for awake fibreoptic intubation: a double-blinded randomized controlled trial.

Authors:  M R Rai; T M Parry; A Dombrovskis; O J Warner
Journal:  Br J Anaesth       Date:  2007-11-23       Impact factor: 9.166

5.  Remifentanil-TCI and propofol-TCI for conscious sedation during fibreoptic intubation in the acromegalic patient.

Authors:  T Cafiero; F Esposito; G Fraioli; G Gargiulo; A Frangiosa; L M Cavallo; N Mennella; P Cappabianca
Journal:  Eur J Anaesthesiol       Date:  2008-04-10       Impact factor: 4.330

6.  A comparison of propofol and remifentanil target-controlled infusions to facilitate fiberoptic nasotracheal intubation.

Authors:  Alexandre Lallo; Valerie Billard; Jean-Louis Bourgain
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

7.  Dexmedetomidine and low-dose ketamine provide adequate sedation for awake fibreoptic intubation.

Authors:  Corey S Scher; Melvin C Gitlin
Journal:  Can J Anaesth       Date:  2003 Jun-Jul       Impact factor: 5.063

8.  Dexmedetomidine, an alpha 2-adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery.

Authors:  R Aantaa; J Kanto; M Scheinin; A Kallio; H Scheinin
Journal:  Anesthesiology       Date:  1990-08       Impact factor: 7.892

9.  Dexmedetomidine as sole sedative for awake intubation in management of the critical airway.

Authors:  Basem Abdelmalak; Laila Makary; Jeremy Hoban; D John Doyle
Journal:  J Clin Anesth       Date:  2007-08       Impact factor: 9.452

10.  The effectiveness of dexmedetomidine infusion for sedating oral cancer patients undergoing awake fibreoptic nasal intubation.

Authors:  Koung-Shing Chu; Fu-Yuan Wang; Hung-Te Hsu; I-Cheng Lu; Hsun-Mo Wang; Cheng-Jing Tsai
Journal:  Eur J Anaesthesiol       Date:  2010-01       Impact factor: 4.330

View more
  24 in total

1.  In reply: is dexmedetomidine or remifentanil alone an optimal sedation scheme for awake intubation?

Authors:  Rong Hu; Hong Jiang
Journal:  J Anesth       Date:  2013-02-05       Impact factor: 2.078

2.  Is dexmedetomidine or remifentanil alone an optimal sedation scheme for awake intubation?

Authors:  Jia Qiang Zhang; Fan Min Meng; Fu Shan Xue
Journal:  J Anesth       Date:  2013-02-03       Impact factor: 2.078

Review 3.  Dexmedetomidine for the management of awake fibreoptic intubation.

Authors:  Xing-Ying He; Jian-Ping Cao; Qian He; Xue-Yin Shi
Journal:  Cochrane Database Syst Rev       Date:  2014-01-19

4.  Comparison of Effects of Different Doses Dexmedetomidine on Inhibiting Tracheal Intubation-Evoked Haemodynamic Response in the Elderly Patients.

Authors:  Guan Zhan-Ying; Wang Chang-Ming; Tang Shuai; Tong Lin-Lin; Han Yu-Feng
Journal:  J Clin Diagn Res       Date:  2015-09-01

5.  Comparison between remifentanil and dexmedetomidine for sedation during modified awake fiberoptic intubation.

Authors:  Hui-Hui Liu; Tao Zhou; Jian-Qi Wei; Wu-Hua Ma
Journal:  Exp Ther Med       Date:  2015-02-13       Impact factor: 2.447

6.  Doxapram hastens the recovery following total intravenous anesthesia with dexmedetomidine, propofol and remifentanil.

Authors:  Huan-Liang Wang; Shu-Hai Tang; Xue-Qin Wang; Wen-Hua Gong; Xiao-Mei Liu; Wei-Fu Lei
Journal:  Exp Ther Med       Date:  2015-02-02       Impact factor: 2.447

7.  Dexmedetomidine for tracheal extubation in deeply anesthetized adult patients after otologic surgery: a comparison with remifentanil.

Authors:  Qing Fan; Chunbo Hu; Min Ye; Xia Shen
Journal:  BMC Anesthesiol       Date:  2015-07-23       Impact factor: 2.217

8.  Comparing Sedation Regimens for Awake Fiberoptic Intubation.

Authors:  Gao-Pu Liu; Fu-Shan Xue; Chao Sun; Gui-Zhen Yang
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

9.  Dexmedetomidine versus remifentanil for sedation during awake intubation using a Shikani optical stylet: a randomized, double-blinded, controlled trial.

Authors:  Ting Xu; Min Li; Cheng Ni; Xiang-Yang Guo
Journal:  BMC Anesthesiol       Date:  2016-08-02       Impact factor: 2.217

10.  Dexmedetomidine-midazolam versus Sufentanil-midazolam for Awake Fiberoptic Nasotracheal Intubation: A Randomized Double-blind Study.

Authors:  Cheng-Wen Li; Yan-Dong Li; Hai-Tao Tian; Xian-Gang Kong; Kui Chen
Journal:  Chin Med J (Engl)       Date:  2015-12-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.